Literature DB >> 15966922

Intense migraines secondary to percutaneous closure of atrial septal defects.

Mohsen Sharifi1, Majid Dehghani, Mahshid Mehdipour, Omar Al-Bustami, Farnaz Emrani, James Burks.   

Abstract

In this study we evaluated the development of migraine after percutaneous closure of atrial septal defect. An abrupt and excruciating form of migraine developed shortly after shunt closure in 5 of 13 consecutive patients undergoing this procedure. A dramatic relief of pain was achieved almost instantaneously after administration of 300 mg of clopidogrel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15966922     DOI: 10.1111/j.1540-8183.2005.04068.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  5 in total

1.  Reversible intracranial parenchymal changes in MRI after MCA aneurysm treatment with stent-assisted coiling technique; possible nickel allergy.

Authors:  Sıla Ulus; Abdullah Yakupoğlu; Ercan Kararslan; Civan Işlak; Aksel Siva; Naci Koçer
Journal:  Neuroradiology       Date:  2012-06-01       Impact factor: 2.804

Review 2.  Atrial septum defect closure device in a beating heart, from the perspective of a researcher in artificial organs.

Authors:  Yasuko Tomizawa
Journal:  J Artif Organs       Date:  2012-06-23       Impact factor: 1.731

3.  Atrial septal defect closure and migraine with aura: is there a correlation?

Authors:  Paola Castellini; Giorgio Lambru; Gian Camillo Manzoni; Paola Torelli
Journal:  Neurol Sci       Date:  2009-05-20       Impact factor: 3.307

4.  New-onset migraine with aura after transcatheter closure of atrial septal defect.

Authors:  Yuji Kato; Daisuke Furuya; Hirotaka Ishido; Toshiki Kobayashi; Norio Tanahashi
Journal:  J Headache Pain       Date:  2012-05-24       Impact factor: 7.277

Review 5.  Migraine Modulation and Debut after Percutaneous Atrial Septal Defect Closure: A Review.

Authors:  Charles Stevens Leger; Joseph F X DeSouza
Journal:  Front Neurol       Date:  2017-03-20       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.